Plain-English translation of NCT01810913 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether two newer treatment approaches work better than the current standard for head and neck cancer patients after surgery. One approach combines and with radiation therapy; the other adds (an immunotherapy drug) to chemotherapy and radiation. All participants receive radiation therapy to the head and neck area, but the additional medications differ depending on which group you're assigned to.
Even after surgery to remove the cancer, some patients with advanced head and neck cancer have a high risk that the cancer will return or spread. This trial is testing whether adding newer medications to the standard radiation therapy can improve survival and reduce the chance of cancer coming back.
You will be randomly assigned to one of three treatment groups. All participants receive intensity-modulated radiation therapy (IMRT) given five days a week for 6 weeks, which targets the cancer area with precision. Depending on your group, you will also receive one of three medication combinations given intravenously (by IV) once weekly during those same 6 weeks. Throughout the trial, you will have blood tests, imaging scans, and follow-up visits to monitor how well the treatment is working and how you are tolerating it. The trial will track your health for several years after treatment ends.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States